Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by MannKind

< Previous 1 2 Next >
MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind to Present at Upcoming Investor Conferences
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
From MannKind
Via GlobeNewswire
Tickers MNKD SCPH
MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association’s 85th Scientific Sessions in Chicago, June 20-23
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind to Present at Upcoming Investor Conferences
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind to Present at Upcoming Investor Conferences
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Expands Executive Leadership Team
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
From MannKind
Via GlobeNewswire
Tickers MNKD
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind to Present at 2024 UBS Healthcare Conference
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
From MannKind
Via GlobeNewswire
Tickers MNKD
More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
From MannKind
Via GlobeNewswire
Tickers MNKD
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.